热门资讯> 正文
Capricor Therapeutics股价为1.5亿美元
2025-12-05 19:33
- Capricor Therapeutics (CAPR) shares popped over 4% premarket on Friday after the biotechnology company priced an offering to raise $150M.
- The offering includes 6M shares of common stock issued at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900K shares.
- The company intends to use the net proceeds from the offering for the continued development and manufacturing of its product candidates, for working capital, and for general corporate purposes.
- The offering is expected to close on or about December 8, 2025, subject to the satisfaction of customary closing conditions.
- CAPR +4.8% premarket to $26.63
- Source: Press Release
More on Capricor Therapeutics, Inc.
- Capricor Therapeutics: Shares Soaring After DMD Study Win - Ball Now In FDA's Court
- Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript
- Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026
- Capricor Therapeutics launches proposed public offering of common stock
- Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
